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Muscular dystrophies are characterized by weakness and wasting of skeletal muscle tissues.
Several drugs targeting the myostatin pathway have been used in clinical trials to increase
muscle mass and function but most showed limited efﬁcacy. Here we show that the
expression of components of the myostatin signaling pathway is downregulated in muscle
wasting or atrophying diseases, with a decrease of myostatin and activin receptor, and an
increase of the myostatin antagonist, follistatin. We also provide in vivo evidence in the
congenital myotubular myopathy mouse model (knock-out for the myotubularin coding gene
Mtm1) that a down-regulated myostatin pathway can be reactivated by correcting the
underlying gene defect. Our data may explain the poor clinical efﬁcacy of anti-myostatin
approaches in several of the clinical studies and the apparent contradictory results in mice
regarding the efﬁcacy of anti-myostatin approaches and may inform patient selection and
stratiﬁcation for future trials.
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Skeletal muscle mass is controlled by different pathwaysamong them myostatin, which is a member of the trans-forming growth factor-beta (TGF-beta) family of proteins
whose function appears to be conserved across species1. Because
several spontaneous mutations in the myostatin gene have been
correlated with muscle hypertrophy in animals (for review see
ref. 2) or even in human3, myostatin inhibition had been seen as a
promising tool to ﬁght muscle atrophy in different diseases
including muscle diseases.
Myostatin is a secreted protein, synthetized by skeletal muscle
as a precursor which undergoes maturation steps4, 5. Several
myostatin inhibitory drugs have been designed targeting different
stages of the myostatin biosynthesis or pathway among them (i)
monoclonal antibodies targeting myostatin, (ii) monoclonal
antibodies targeting myostatin’s receptor AcvRII, (iii) AcvRII
decoys, (iv) follistatin overexpression which functions as a
myostatin antagonist by preventing receptor binding (for review
see ref. 6). During the last 15 years, at least six molecules (MYO-
029, BMS-986089, PF-06252616, ACE-083/-031, BYM338, FS-
344) have been developed by pharmaceutical companies to block
myostatin pathways (https://clinicaltrials.gov). These molecules
are/were evaluated in several neuromuscular diseases that show
muscular wasting or atrophy but so far the published results were
largely disappointing. Signiﬁcant improvements in muscle
strength or physical function have not been reached7–9 with the
exception of two small open-label studies using an AAV vector
encoding the follistatin isoform FS344 intramuscularly injected in
Becker Muscular Dystrophy (BMD, n= 6) patients and in
Inclusion Body Myositis (IBM, n= 6)10–12 and 1 small rando-
mised controlled trial using a monoclonal antibody against the
AcvRII receptor in IBM patients (n= 11 active, 3 placebo)13.
Several explanations have been proposed, among them the spe-
ciﬁcity of the drugs themselves and the possibility that they do
not target the correct form of myostatin or target other growth
factors besides myostatin implicated in muscle mass regulation.
However, in animals, several laboratories including ours have
demonstrated that myostatin pathway inhibition leads to muscle
hypertrophy and enhances tetanic force in controls or in several
murine models of muscle diseases such as the mdx mouse, a
murine model for Duchenne Muscular Dystrophy (DMD)14, 15.
We hypothesized that another possible explanation for the poor
clinical efﬁcacy of anti-myostatin molecules in several of the
human studies was that the expression level of the targeted protein
itself was reduced. Indeed, one can easily imagine that a treatment
targeting circulating myostatin may not work if the level of cir-
culating myostatin is already very low in patients. So far, only a few
articles have described the expression levels of circulating myos-
tatin in patients16–18. In our study, the expression levels of different
actors of the myostatin network were analyzed at messenger RNA
(mRNA) and/or protein levels in the sera and/or biopsies of
patients with different muscular diseases and in a mouse model of
congenital myotubular myopathy. Our data show that in several
neuromuscular diseases the myostatin pathway is shut down at
mRNA level in muscle biopsies, leading to low levels of circulating
and endogenous muscle myostatin and high-levels of follistatin.
The regulation of the myostatin network is disease-dependent, the
patients affected by the most atrophying disease showing the
strongest extinction of the myostatin pathway. Further inhibition
of this pathway by an exogenous compound (monoclonal antibody
or vector-mediated inhibition) in the presence of strong down-
regulation in severely affected muscles may not be an efﬁcient
strategy to increase muscle mass, even though this blockage is
reversible upon proper treatment of the primary cause of the dis-
ease, as exempliﬁed by the myotubular myopathy model. These
data may explain the poor clinical efﬁcacy of most anti-myostatin
approaches for neuromuscular diseases to date and may affect
patient selection and stratiﬁcation for future trials.
Results
Concentration of serum myostatin in neuromuscular diseases.
Serum concentrations of myostatin (MSTN or GDF8), follistatin
(FSTN), GDF11 and ACTIVIN A were determined in patients
affected by several neuromuscular diseases with various levels of
muscle atrophy and in controls (summarized in Table 1 and Sup-
plementary Table 1). BMD and DMD share similar clinical signs and
symptoms including muscle weakness and atrophy but in BMD,
symptoms are milder and patients have a later onset19. Both DMD
and BMD are caused by different mutations in the DMD gene but
mutations in DMD patients lead to an absence of any functional
dystrophin protein whereas mutations in BMD patients lead to a less
functional protein. Spinal Muscular Atrophy (SMA) is characterized
by a loss of motor neurons leading to muscle wasting often leading to
premature death20. Inclusion-Body Myositis (IBM) is the most
common age-related muscle disease in the elderly and characterized
by a slowly progressive inﬂammatory and degenerative myopathy
resulting in chronic muscle weakness and atrophy21. Facioscapulo-
humeral Dystrophy (FSHD) is the most common muscular dystro-
phy in adults characterized by the selective atrophy of groups of
muscles22. Finally, Myasthenia Gravis (MG) is the most common
primary disorder of neuromuscular transmission, caused by anti-
bodies to the acetylcholine receptor leading to muscle weakness
usually without severe muscle atrophy23. For ACTIVIN A, a trend to
a lower expression in SMA and DMD patients (p= 0.06 for both,
one-way ANOVA test, followed by the Fisher’s Least Signiﬁcant
Difference multiple comparison test) was noted (Fig. 1a). No mod-
iﬁcation of GDF11 was noted, except in SMA sera in which a massive
overexpression was observed (Fig. 1b). Concerning GDF8, in the
most atrophic (SMA) and most wasting (DMD) muscle diseases
studied a two-fold or higher decrease of circulating GDF8 was
Table 1 Characteristics of patients’ sera
Ctrl (n= 9) BMD (n= 6) SMA (n= 4) DMD (n= 5) IBM (n= 54) MG (n= 12) FSHD (n= 13)
Age (years) Mean 34.2 18.3 11.0 9.2 64.9 46.6 46.8
Range 23.1–45.3 7.2–48.7 8.9–12.9 6.0–13.9 41.3–87.1 16.5–64.3 14.5–61.2
Gender Female 6 – 1 – 17 7 4
Male 3 6 3 5 37 5 9
Age of onset (years) Mean – Early childhood Infant Early childhood 56.5 37.3 20
Range – Early childhood Infant Early childhood 35–82 14.5–62.3 2–49
Time elapsed (years) Mean – – – – 9.5 9.3 11.1
Range – – – – 2.7–45.5 2.0–23.9 5.2–13.7
Time elapsed: number of years between the age at evaluation and the age of onset
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observed (SMA 30.6%± 13.7 and DMD 50.6%± 17.18 GDF8 com-
pared with controls, respectively) (Fig. 1c). Associated with this GDF8
decrease, an important trend to an increase of circulating FSTN was
observed (SMA 135.6%± 71.3 and DMD 189.4%± 35.2 compared
with controls, respectively) (Fig. 1d). BMD, IBM, and FSHD patients,
who clinically show a less pronounced muscle atrophy, have higher
circulating myostatin than DMD and SMA patients but less than
controls (BMD 71%± 23.7, IBM 71%± 55.6 and FSHD 66%± 35
compared to controls, respectively). The levels of circulating FSTN
were not increased in BMD patients (85.5%± 22.4) whereas a trend
to an increase was observed in both IBM and FSHD patients (146.3
± 70.9 and 145.8± 72.8). In MG patients, who do not show any
atrophy, no modiﬁcation of GDF8 nor FSTN was observed. Impor-
tantly, regarding all these effectors of the myostatin pathway, an
important variation across samples is observed in IBM and FSHD
patients, suggesting that the myostatin pathway may be signiﬁcantly
down-regulated in some patients whereas there is still preserved
myostatin expression in others. A correlation test was performed
between GDF8 and FSTN levels, but no correlation was found.
Expression of genes implicated in the myostatin pathway. As
GDF8 is mainly produced by skeletal muscle, the mRNA
expression levels of several genes implicated in the myostatin
pathway were investigated in muscle biopsies (summarized in
Table 2). Unfortunately, SMA skeletal muscle could not be stu-
died as the diagnosis is essentially genetic and a muscle biopsy is
not normally performed in SMA patients. No modiﬁcation of the
expression of either ACTIVIN A (Fig. 2a) or GDF11 (Fig. 2b) was
observed even if a trend to an overexpression of GDF11 was
noted. A massive down-regulation of GDF8 was observed in both
the DMD and IBM patients as only 8 and 12% of the respective
mRNA levels were detectable (Fig. 2c). At the same time, FSTN
was up-regulated by 2.7 fold in IBM patients (p= 0.039) (Fig. 2d).
Interestingly, the myostatin receptor ACVRIIB was strongly
down-regulated in both DMD (30% of residual mRNA, p= 0.014)
and IBM (40% of residual mRNA, p= 0.07) but up-regulated in
FSHD (+28%, p= 0.006) (Fig. 2e). In Limb-Girdle Muscular
Dystrophy (LGMD) and BMD, no signiﬁcant modiﬁcation of
muscle GDF8, FSTN, or ACVRIIB was observed. An important
variability across LGMD and BMD samples was observed but the
most atrophying disease (DMD) showed again a general down-
regulation of the myostatin pathway. No correlation was found
between GDF8, ACVRIIB, and FSTN in all individual diseases.
However, concerning FSHD patients, FSHD1 patients express less
GDF8 than FSHD2 patients (p= 0.048), but no difference was
observed in FSTN (Supplementary Fig. 1). FSHD2 patients
showed a trend to express more ACVRIIB than FSHD1 (+120%,
p= 0.08). Finally, because fat replacement is not identical in all
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Fig. 1 Circulating levels of GDF8, FSTN, ACTIVIN A and GDF11. Circulating levels of either ACTIVIN A a, GDF11 b, GDF8 c and FSTN d were measured in
healthy control (Ctrl, N= 9), Becker Muscular Dystrophy (BMD, N= 6), Spinal Muscular Atrophy (SMA, N= 4), Duchenne Muscular Dystrophy (DMD,
N= 4), Inclusion Body Myositis (IBM, N= 54), Myastenia Gravis (MG, N= 12) or Facioscapulohumeral Dystrophy (FSHD, N= 13) patients. Horizontal lines
are medians, the extremities of the boxes are delimitated by the ﬁrst and third quartile, and the whiskers correspond to the 10th and 90th percentile. A
one-way ANOVA, followed by the Fisher’s Least Signiﬁcant Difference multiple comparison test was performed. Degree of freedom= 6
Table 2 Characteristics of patients’ biopsies
Ctrl (n= 9) BMD (n= 6) DMD (n= 17) IBM (n= 17) FSHD (n= 13) LGMD (n= 11)
Age (years) Mean 43.2 32.5 9.7 70,5 45.0 28.8
Range 24.0–69.0 1.6–61.3 0.8–15.7 56.9–81.0 13.0–79.4 8.6–57.9
Gender Female 6 – – 3 5 5
Male 3 6 17 14 8 6
Age of onset (years) Mean – 23.75 3.3 65.4 27.2 23.3
Range – 5–48 2–6 45–78 16–40 4–55
Time elapsed (years) Female – 17.7 7 5 21.5 6.7
Male – 1.5–36.3 0.7–12.7 0.7–18.5 2.5–38.5 1.9–15.1
Time elapsed: number of years between the age at evaluation and the age of onset
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and ACVRIIB were normalized by the expression of the MLC-3
fast myosin heavy chain (encoded by the MYL1 gene which is
expressed in adult in fast muscles24), and similar results were
obtained (Supplementary Fig. 2).
Myostatin levels impact anti-myostatin approaches. To deter-
mine whether or not the endogenous expression level of the
myostatin pathway could impact on the success of anti-myostatin
approaches, we used the Mtm1-KO mouse model. We have
chosen the Mmt1-KO model because X-linked myotubular
myopathy (XLMTM), which is a severe congenital disease due to
mutations in the myotubularin coding gene MTM1, is char-
acterized by generalized muscle hypotrophy and weakness25 and
this mouse model recapitulates the muscle atrophy. Moreover, the
XLMTM muscle phenotype can be corrected by AAV-mediated
gene replacement therapy in the Mtm1-KO mouse model of the
disease26, 27.
Three week old myotubularin KO (Mtm1-KO) and wild type
(WT) mice were intramuscularly (in the tibialis anterior (TA))
injected with an AAV coding the myostatin pro-peptide D76A
mutant (AAV-PropD76A). While an increase in muscle weight
was observed in the WT mice after injection (mean weight= 28.9
± 0.6 g vs. 35.8± 0.9 g for phosphate buffer saline (PBS) and
AAV-propD76A injected TA, respectively) p= 1.16.10e-10), no
muscle growth was observed in theMtm1-KO mice (11.7± 0.7 vs.
11± 1.8 g, respectively, p> 0.05) (Fig. 3a). Because at 3 weeks,
Mtm1-KO mice already show an important loss of muscle weight
of the tibialis anterior compared with WT littermates (6.5± 0.9 g
vs. 7.8± 2.2 at 14 days, 8.6± 1.4 g vs. 16.9± 2.8 at 21 days and
8.9± 1.9 g vs. 25.8± 1.6 at 30 days for the Mtm1-KO and WT
mice respectively, Fig. 3b), the expression level of the myostatin
network was investigated. A strong down expression of Gdf8
(47.6%± 18.6% of mRNA compared to WT mice at 14 days,
22.5%± 7.8% at 21 days and 25%± 6.5% at 30 days, Fig. 3c),
associated with a massive up-regulation of Fstn (159%± 44.9% of
mRNA compared with WT mice at 14 days, 567%± 201% at day
21 and 768%± 190% at day 30, Fig. 3d) and of Gdf11 (112%±
18% of mRNA compared with WT mice at day 14, 349% ± 38% at
day 21, 178%± 49% at day 30, Fig. 3e) were observed. AcvrIIb
and Activin A expressions were only barely affected (Fig. 3f, g).
These results strongly suggest a correlation between the low
expression of expression of GDF8 and atrophy. This correlation
was conﬁrmed by analyzing the weight and Gdf8 expression in 2
other muscles of the Mtm1-KO mouse (Supplementary Fig. 3). In
the quadriceps, which is less affected than the TA, there is loss of
muscle weight of 25%± 15% at day 21 and of 46%± 10% at day
35. The level of Gdf8 is 71%± 44 and 38%± 29% at day 21 and
day 35, respectively, compared with the WT animals. Finally, in
the least affected muscle, the soleus, there is no muscle loss at day
21, and the myostatin level is unchanged. However, at day 35, the
muscle has lost 23%± 6% of mass and the Gdf8 level has been
reduced by 21%± 27%. These data suggest that inhibiting the
myostatin pathway in an atrophic muscle might not be a
successful therapeutic strategy in the Mtm1-KO mice at the time










Ctrl BMD DMD IBM FSHD LGMD
Ctrl BMD DMD IBM FSHD LGMD
Ctrl BMD DMD IBM FSHD LGMD

























































































Fig. 2Myostatin pathway in muscle biopsies. mRNA levels of either ACTIVIN A a, GDF11 b, GDF8 c, FSTN d, or ACTIVIN A e were measured by RT-qPCR in
healthy controls (Ctrl, N= 9), Becker Muscular Dystrophy (BMD, N= 6), Duchenne Muscular Dystrophy (DMD, N= 17), Inclusion Body Myositis (IBM,
N= 17), Facioscapulohumeral Dystrophy (FSHD, N= 13) or Limb Girdle Muscular Dystrophy (LGMD, N= 11) patients. Horizontal lines are medians, the
extremities of the boxes are delimitated by the ﬁrst and third quartile, and the whiskers correspond to the 10th and 90th percentile. A one-way ANOVA,
followed by the Fisher’s Least Signiﬁcant Difference multiple comparison test was performed. Degree of freedom= 5
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dramatically down-regulated with 4.4-fold decrease of Gdf8
mRNA and a 5.6-fold increase of Fstn mRNA in the TA of 3
week-old Mtm1-KO mice.
The tibialis anterior muscles of WT or Mtm1-KO mice were
next intramuscularly injected with either an AAV coding the
Mtm1 gene (AAV-Mtm1) or a combination of the AAV-Mtm1
gene and the AAV-PropD76A. In the presence of the Mtm1
protein, muscle histology was greatly improved with an increase
of cross-sectional ﬁber size, and an improved intracellular
architecture revealed after NADH-TR staining (Supplementary
Fig. 4). The abnormal localizations of the dihydropyrine 1α
receptor (DHPR1α) and ryanodine receptor 1 (RYR1) were
partially restored. In the Mtm1-KO mice, the muscle mass was
improved in the presence of the AAV-Mtm1 (148.1%± 12.9% of
residual mRNA, p= 5.3 10e-6 compared with the Mtm1-KO
injected with PBS) whereas no modiﬁcation of muscle mass was
observed in the WT mice (Fig. 4a). Interestingly, the presence of
both AAV-Mtm1 and AAV-PropD76A allowed a further increase
in muscle mass in the Mtm1-KO mice (179%± 25.2%, p= 7.15
10e-11, compared with the TAs injected with PBS). A similar
effect was observed in the WT mice (123.3%± 6.8%, p= 8.5 10e-9






































































14 21 30 14 21
0.06












































a b c d
e f g
Fig. 3 Myostatin network in the tibialis anterior of Mtm1-KO mice. The tibialis anterior (TAs) of 3 week-old Mtm1-KO mice (KO), or wild type littermates
(WT), were injected with either PBS or an AAV vector coding the myostatin pro-peptide D76A mutant (PropD76A) and 2 weeks later, mice were
sacriﬁced and the TAs were weighed a. The weights b, Gdf8 c, Fstn d, Gdf11 e, AcvRIIb f, or Activin A g mRNAs were measured at 14, 21, or 30 day old in the
TAs of either Mtm1-KO mice (KO) or wild type littermates (WT) (n= 4 and 8 at day 14, 8 and 9 at day 21, 9 and 9 at day 30 for KO and WT mice
































































































































Fig. 4 Mtm1 rescue in Mtm1-KO mice. The tibialis anterior (TAs) of 3 week-old Mtm1-KO mice were injected with either PBS, an AAV vector coding Mtm1
(Mtm1) or 2 AAVs coding Mtm1 and propD76A (Mtm1 + PropD76A). Two weeks later, mice were sacriﬁced and the TAs were weighed a and the
expression levels of GDF8 b, Fstn c and AcvRIIb dmRNAs were measured (n= 7 (PBS), 5 (Mtm1), 4 (Mtm1 + PropD76A)). All graphs represent mean± SD,
with p values calculated by a one-way ANOVA, followed by the Fisher’s Least Signiﬁcant Difference multiple comparison test
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both Mtm1-KO and WT mice, the simultaneous injection of
AAV-PropD76A + AAV-Mtm1 led to a higher increase in muscle
mass than AAV-Mtm1 alone (Fig. 4a).
To determine if the myostatin pathway was restored by the
expression of Mtm1 in the Mtm1-KO mice, the expression levels
of Gdf8, Fstn, and AcvRIIb were analyzed in the transduced TAs.
An increase of Gdf8, associated with a decrease of Fstn was
observed in the presence of Mtm1 (Fig. 4b, c), without
modiﬁcation of AcvRIIb level (Fig. 4d). The combination of
myostatin pathway inhibition and Mtm1 rescue enhanced both
the Gdf8 increase and the Fstn decrease (Fig. 4b, c). These results
suggest that the expression of myotubularin in the Mtm1-KO
mice leading to a 2.4-fold increase of Gdf8 and a 2.8-fold decrease
of Fstn was sufﬁcient to enable an anabolic effect of the myostatin
propeptide on muscle mass. The muscle atrophy observed in the
Mtm1-KO mice may not be due to an up-regulation of the
myostatin pathway but rather a consequence of the absence of
myotubularin.
Discussion
During the past 12 years at least 15 clinical trials aiming at
inhibiting the myostatin pathway have been carried out to
improve muscle mass and function in muscular diseases, and
several of these studies are still underway (https://clinicaltrials.
gov/). Different pathologies were targeted among them BMD,
DMD, LGMD, IBM, and FSHD. The concept of anti-myostatin
therapy for neuromuscular diseases has been based on the pos-
tulate that inhibiting this pathway in patients might lead to an
increase in muscle mass and muscle strength/function as it does
in normal muscle, which implies that the level of circulating
myostatin is high enough to be down-regulated by such a ther-
apeutic approach. However, the results were disappointing: (i) the
injection of MYO-29, a recombinant human neutralizing anti-
body to myostatin, in adult muscular dystrophies (BMD, FSHD,
and LGMD) did not improve any of the outcome measures
(strength, lean body mass, muscle volume)8. (ii) DMD patients
treated with ACE-031, a soluble form of activin type IIB receptor,
showed a very slight increase in total body lean mass (+4.1%
compared with +2.6% in the placebo group) and a non-
statistically signiﬁcant trend for maintenance of 6 min walk test
was observed in the ACE-031 treated group, although the study
had to be interrupted after 12–16 weeks due to safety concerns9.
(iii) For sIBM patients treated with bimagrumab, a human
monoclonal antibody targeting activin receptors IIA and IIB, a
potential beneﬁt in a patient reported outcome (disability scale)
was shown, an increased muscle and lean body mass was
observed, as well as an improvement in the 6-min walking test in
a single dose phase 2 study13. However, Novartis has recently
announced that, in a late-stage phase2b/3 study, bimagrumab had
not met its primary endpoint (6-min walk distance) and did not
improve muscle strength (quantitative muscle testing)28; (iv)
Only one approach in two small phase two open-label studies
showed preliminary promising results: in BMD patients, multiple
intramuscular injections in three of the four muscles forming the
quadriceps of an AAV vector encoding the follistatin isoform
FS344 showed an improvement of the 6 min walk test at
6 months post injection10, 11. A similar therapeutic approach in
IBM patients shown an improvement of the 6 min walk test by 56
m/year (distance annualized to a median 1-year change)12. Cur-
rently, several clinical trials are underway and results are expected
next year.
Different possibilities could explain this absence of functional
improvement, among them the drug pharmacokinetics/pharma-
codynamics (PK/PD) in the conditions studied so far in humans.
A retrospective analysis demonstrated that central clearance of
MYO-029 in humans is greater than 2-fold than typical IgG1
mAbs and PK/PD analyses in monkeys suggested that peak and
steady state exposures in the MYO-029 trial might achieve only
50 and 10% of the maximum effect seen in monkeys. This would
explain why the MYO-029 had a low probability to induce a
muscle mass increase in patients29. Another explanation could be
the lack of speciﬁcity of the drugs themselves, GDF8 and
GDF11 sharing 90% in their mature region for example. Finally,
GDF8 might not be the only ligand implicated in muscle growth
to bind ACVRIIB, as it was demonstrated that blocking AcvRIIb
in Gdf8 deﬁcient mice further enhances muscle mass30. Finally,
ACTIVIN A has been described as more prominently regulating
muscle mass in primates than does GDF831.
In our study, we have explored another confounding possibility
based on the expression levels of circulating and muscle-
endogenous proteins implicated in the myostatin pathway.
Recently, by using an immunoafﬁnity (LC–MS/MS) assay, Burch
et al.16 have published that serum myostatin concentrations are
reduced in patients with muscle diseases. They concluded that
because myostatin is mainly produced by muscle tissue, these
reduced circulating myostatin levels may reﬂect the net loss of
functional muscle mass. Our data however do not support this
hypothesis. Indeed, we have observed that whole myostatin
pathway is strongly altered in the most atrophying neuromus-
cular diseases, at both mRNA and protein levels, and that the
lower expression of serum myostatin is associated with a reduced
muscle expression of GDF8 mRNA. These results indicated that
reduced circulating myostatin levels are not, or at least not only,
the reﬂection of muscle loss but represent an altered myostatin
regulation of the diseased tissue. In agreement with this
assumption, normalization of myostatin levels against MLC3 did
not alter the results, supporting the notion that net muscle loss is
not the driver of myostatin reduction. In addition, the muscle
atrophy observed in DMD patients is not the consequence of an
activation of the myostatin pathway nor to an overexpression of
ACTIVIN A. On the contrary, our data indicate that the myos-
tatin pathway, including ACTIVIN A expression, may be
intrinsically down-regulated in atrophying or wasting muscle
diseases to counterbalance the wasting process. Interestingly,
whereas GDF8 and GDF11 are highly homologous, no mod-
iﬁcation of GDF11 was observed in patient’s sera with the
exception of SMA, suggesting that these 2 factors have different
biological roles. The down-regulation of the myostatin pathway in
human could explain the apparently contradictory results in mice
and humans regarding the efﬁcacies of anti-myostatin approa-
ches. Indeed, the outcomes of a clinical trial in DMD patients was
not encouraging9, while myostatin pathway blockade has been
successful in mdx mice14, 15, 32. Despite the fact that Duchenne
patients and mdx mice share a mutation in the same gene, no
important muscle atrophy is observed before 6 months of age in
the mdx mouse33, 34 and experiments are usually performed
before this age. Moreover, even if myostatin levels are lower in
mdx mouse than in wild-type mouse, the endogenous circulating
myostatin level is at least 50 times higher in mice than in
humans16. This could be one of the reasons why anti-myostatin
approaches in the mdx model were successful.
Finally, one of the most important questions raised by our
work concerns the usefulness of blocking the myostatin pathway
in diseases in general and in neuromuscular diseases in particular.
Concerning the non-muscular diseases in which the main affected
organ is not the muscle (such as cancer), a deep experimental
evaluation of the therapeutic potential of the anti-myostatin
approaches needs to be performed. Concerning the neuromus-
cular diseases, in slowly progressive pathologies such as BMD or
FSHD, an important variability of both myostatin and follistatin
circulating proteins is observed across samples, suggesting that at
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01486-4
6 NATURE COMMUNICATIONS |8:  1859 |DOI: 10.1038/s41467-017-01486-4 |www.nature.com/naturecommunications
least some patients may be eligible for an anti-myostatin
approach. However, in the most wasting neuromuscular dis-
eases such as DMD, the whole myostatin pathway is down-
regulated. Interestingly, in the Mtm1-KO mouse model, the
restoration ofMtm1 expression is associated with a normalization
of the myostatin pathway, indicating by analogy that at least
partial restoration of the dystrophin protein might be necessary
before the inhibition of myostatin. Such an assumption is sup-
ported by the higher circulating myostatin levels in BMD com-
pared with DMD, and experimentally by the stronger effect of
anti-myostatin therapy in mdx mice if complemented by dys-
trophin restoration through exon skipping14, 32. Therefore, for
future trials of anti-myostatin therapy patient eligibility should be
tested by ascertaining sufﬁcient levels of the therapy target and
taking into account that general circulating myostatin levels may
not be representative of the muscle-intrinsic levels of affected
target muscles. Furthermore, in the most atrophying diseases, the
mutated gene might need to be rescued ﬁrst in order to restore
myostatin expression before inhibiting the myostatin pathway
becomes a therapeutic option.
Methods
Patients. The collection of sera and biopsies were approved by the “Comité de
Protection des Personnes” Paris VI and the French regulatory agency (ANSM)
(CCP#99–12, ID RCB 2012-A01277-36), the research and Development Ofﬁce
(#DN 12DN29), and the East Central London Research Ethics Committee 1
(reference number 10/H0721/28 and 12/LO/1557—Queen Square REC). An
informed consent was obtained from all subjects. The characteristics of the patients
are described in Tables 1 and 2 and Supplementary Table 1.
Mouse experiments. Mice were handled according to French and European
legislation on animal care and experimentation, and protocols were approved by
the institutional ethical committee. The constitutive knock-out of the myotubularin
gene (Mtm1-KO, also named BS53d4-129pas) was generated previously by
homologous recombination35. Wild-type littermate males were used as controls.
Sample size was chosen based on previous experience in the laboratory with the
mouse model and response to treatments. No pre-established inclusion/exclusion
criterion was applied. Animal were not randomized for allocation in the experi-
mental groups and animal studies were not performed under a blinding procedure.
Only males were used in the experiments.
Generation of recombinant AAV vector and delivery. A recombinant serotype 1
AAV vector containing mutated myostatin propeptide D76A under the CMV
promoter (AAV-PropD76A) was produced, as previously described36. Mouse
Mtm1 complementary DNA (cDNA) (AF073996, NCBI) was cloned in the AAV
expression pGG2-DES plasmid, which contains the human desmin promoter.
Recombinant serotype 1 viral particles (AAV1-Mtm1) were obtained by a tri-
transfection procedure from HEK293 cells as previously described26. Vector titers
were expressed as viral genomes per ml (vg/ml).
AAV vectors were intramuscularly delivered to 3 week-old KO male mice and
age matched wild type males. Mice were anesthetized by intraperitoneal injection of
5 μL/body gram of ketamine (20 mg/mL, Virbac) and xylazine (0.4%, Rompun,
Bayer). TA muscles were injected with 3.5 × 109 vg of AAV-CMV- PropD76A, 5 ×
109 vg of AAV-Mtm1 or sterile PBS solution. Muscles were dissected 14 days after
injection and frozen in either liquid nitrogen-cooled isopentane or liquid nitrogen
for histological and molecular assays.
ELISA analysis. Peripheral venous blood was collected from healthy and patients’
volunteers using serum separator tubes (10 mL). After 30 min on the benchcoat at
room temperature, the tubes were centrifuged at 2000 rpm for 10 min at 4 °C. The
collected serum (5 mL) was aliquoted and stored at −80 °C until further use. The
concentrations of either GDF8, FOLLISTATIN, GDF11, or ACTIVIN A in the sera
were measured using an ELISA kit (respectively # DGDF8, # DFN00, # DY1958,
and # DAC00B R&D Systems Europe, Ltd, Abingdon, United Kingdom) according
to the manufacturer’s instructions. The optical density was measured using a
microplate reader (Inﬁnite 200 Pro, Tecan Group Ltd., Männedorf, Switzerland).
Importantly, the myostatin immunoassay was designed to recognize mature GDF8.
According to the manufacturer, no signiﬁcant cross-reactivity or interference was
observed in the presence of 50 ng/ml (20 times more than the highest value
measured in our experiment) of different proteins including the GDF8 propeptide,
GDF11 or GDF15. We have experimentally conﬁrmed this result by using 4000 pg/
ml of recombinant GDF11. The absence of cross reactivity with FOLLISTATIN
(8000 pg/ml) and ACTIVIN A (4000 pg/ml) was also experimentally validated.
RNA extraction and real-time PCR. For murine samples, total RNA was puriﬁed
from muscles of males using TRIzol reagent (Life Technologies, Saint Aubin,
France) according to manufacturer’s instructions. RNA concentration was mea-
sured by spectrophotometry (OD 260 nm) using a nanodrop ND-1000 spectro-
photometer (Thermo Scientiﬁc, Wilmington, DE, USA) and RNA integrity was
veriﬁed by electrophoresis using ethidium bromide. After DNAse treatment
(Ambion), RNA was reverse transcribed using Super Script II RNase H Reverse
Transcriptase (Invitrogen) in the presence of Random Primers (Promega). Real-
time PCR was performed at 60 °C as melting temperature and with primers
described in Supplementary Table 2 using an ABI Prism 7900 apparatus (Applied
Biosystems) in a ﬁnal volume of 25 µl with reverse transcriptase, forward and
reverse primers (0.5 nmol/ml) and SYBRGreen Mastermix (Roche, Basel,
Switzerland).
For human samples, cryopreserved tissues were transferred in tube containing
1.4 mm ceramic beads (Precellys, Bertin Corp, Maryland, United State) plus 1 mL
of Trizol (Life technologies, Saint Aubin, France) and shaked three times at 5700
rpm for 30 s. Between each cycle, tubes were incubated in ice during at least 1 min.
Total RNAs were extracted using trizol according to the manufacturer’s protocol
(Life technologies, Saint Aubin, France). The quantity of RNA was determined
using a nanodrop ND-1000 spectrophotometer (Thermo Scientiﬁc, Wilmington,
DE, USA). The reverse transcription was described previously and realized on 1 µg
of total RNA in a ﬁnal volume of 10 µl using the transcriptor ﬁrst strand cDNA
synthesis kit (Roche, Meylan, France)37. qPCRs were performed on a LightCycler
480 Real-Time PCR System (Roche, Meylan, France) in a ﬁnal volume of 9 µl with
0.4 µl of reverse transcriptase (RT) product, 0.18 µl each of forward and reverse
primers (20 pmol/ml) and 4.5 µl of SYBRGreen Mastermix (Roche, Basel,
Switzerland). After qPCR, the PCR products were run on a 2% agarose gel and
were cloned using the Topocloning kit (Life Technologies, Saint Aubin, France)
and sequenced. Primers used in this study are described in Supplementary Table 1.
Quantitative PCR (qPCR) was designed according to the MIQE standards38.
Among the 87 items to review, 57 were classiﬁed as essential. All were followed. In
particular, to determine the best human housekeeping gene, ﬁve genes were
evaluated: B2M, GAPDH, GUS, P0, and PPIA. A MANOVA test has demonstrated
that none of these genes were suitable for housekeeping since signiﬁcant statistical
changes were observed between the different groups. GUS, P0, and PPIA were then
chosen to calculate the expression normalization factor for each sample using
geNorm software (V3.5). To determine the best housekeeping mouse gene, 6 genes
were evaluated: Gapdh, P0, Hprt1, β-actin, β-tubulin, and 18 S, and P0 was chosen.
Statistical analysis. A one-way ANOVA was used for all the experiments, fol-
lowed by the Fisher’s Least Signiﬁcant Difference multiple comparison test. A
sample-size power analysis was not performed. Differences were considered to be
statistically different at p*< 0.05; **<0.01; ***<0.001
Data availability. All relevant data are available from the authors upon reasonable
request.
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